Corcept Therapeutics (CORT) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)

Corcept Therapeutics (CORT) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 45.47%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -3.84%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 91.31%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Corcept Therapeutics 9.56 Bn 9.22 Bn 162.02 Mn -58.39%

Historic Data

Download Data
DateValue
Mar 31, 2026 -58.39%
Dec 31, 2025 13.08%
Sep 30, 2025 -17.56%
Jun 30, 2025 8.10%
Mar 31, 2025 -3.81%
Dec 31, 2024 -1.76%
Sep 30, 2024 15.29%
Jun 30, 2024 9.81%
Mar 31, 2024 5.45%
Dec 31, 2023 6.18%
Sep 30, 2023 12.96%
Jun 30, 2023 -1.16%
Mar 31, 2023 -19.30%
Dec 31, 2022 -17.44%
Sep 30, 2022 9.45%
Jun 30, 2022 10.67%
Mar 31, 2022 7.69%
Dec 31, 2021 13.37%
Sep 30, 2021 19.74%
Jun 30, 2021 13.38%